CTLA4 and sarcoma: Although three–four cycles of anti-CTLA-4 antibody are administered in clinical trials of sarcoma and other tumor patients [45,46,47], we administered three cycles of anti-CTLA-4 antibody in the present study based on previous preclinical reports [22,35,47], allowing us to compare our data with other reports.